← All Ars Pharmaceuticals, INC filings

Ars Pharmaceuticals, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
SPRY
Ars Pharmaceuticals, INC
10-K: ARS Pharmaceuticals Reports Positive 2024 Results, Highlights Neffy's Market Launch and Strategic Collaborations
ARS Pharmaceuticals highlights the FDA and European Commission approval and commercial launch of Neffy, along with strategic partnerships to expand its global reach.
NASDAQ
SPRY
Ars Pharmaceuticals, INC
10-K: ARS Pharmaceuticals 10-K Filing: Neffy Development and Commercialization Strategy
ARS Pharmaceuticals' 10-K filing details the company's progress in developing Neffy, a needle-free epinephrine nasal spray, and its plans for commercialization.